Recombinant lentivirus with enhanced expression of caudal‑related homeobox protein 2 inhibits human colorectal cancer cell proliferation in vitro

He,Sai; Sun,Xue‑Jun; Zheng,Jian‑Bao; Qi,Jie; Chen,Nan‑Zheng; Wang,Wei; Wei,Guang‑Bing; Liu,Dong; Yu,Jun‑Hui; Lu,Shao‑Ying; Wang,Hui

doi:10.3892/mmr.2015.3594

August-2015 Volume 12 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2015 Volume 12 Issue 2

Full Size Image

Article Open Access

Recombinant lentivirus with enhanced expression of caudal‑related homeobox protein 2 inhibits human colorectal cancer cell proliferation in vitro

Authors:
- Sai He
- Xue‑Jun Sun
- Jian‑Bao Zheng
- Jie Qi
- Nan‑Zheng Chen
- Wei Wang
- Guang‑Bing Wei
- Dong Liu
- Jun‑Hui Yu
- Shao‑Ying Lu
- Hui Wang
View Affiliations / Copyright

Affiliations: Department of General Surgery, First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Second Department of Cardiovascular Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China, Department of Anesthesiology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China

Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
Pages: 1838-1844
|
Published online on: April 3, 2015

https://doi.org/10.3892/mmr.2015.3594
Expand metrics +

Abstract

Caudal‑related homeobox protein 2 (CDX2), a tumor suppressor in the adult colon, is overexpressed under a non‑cancer specific cytomegalovirus promoter in certain tumor cells; furthermore, non‑specific expression of CDX2 may result in aberrant side effects in normal cells. The human telomerase reverse transcriptase (hTERT) promoter is active in the majority of cancer cells but not in normal cells. Hypoxia is a key feature of solid tumors, and targeted genes may be significantly upregulated by five copies of hypoxia‑response elements (HREs) under hypoxic conditions. However, the effect of CDX2 overexpression, as controlled by five copies of HREs and the hTERT promoter, on human colorectal cancer (CRC) cell proliferation in vitro remains to be fully elucidated. In the current study, a recombinant lentivirus containing the CDX2 gene under the control of five HREs and the hTERT promoter was generated. An immunofluorescence assay was used to detect CDX2 expression by the 5HhC lentivirus, whereas an MTT assay was used to detect the effects of CoCl2 on the viability of LoVo cells. Western blot analysis was conducted in order to determine the relative ratios of recombinant CDX2 protein to the internal control β-actin, following 5HhC/LoVo cell culture under normoxic and hypoxic conditions (100, 200, 300, 400 or 500 µmol/l CoCl2) for 24 h, then for 12, 24 or 36 h with the optimal concentration (300 µmol/l) of CoCl2. Reverse transcription polymerase chain reaction analysis was used to determine the transcription of recombinant CDX2 mRNA following culture of 5HhC/LoVo cells under normoxic or hypoxic conditions. Finally, a cloning assay was used to detect the proliferative ability of 5HhC/LoVo and 5Hh cells. High CDX2 expression was observed in hTERT‑positive LoVo cells under hypoxic conditions, an effect which was mimicked by treatment with CoCl2 to inhibit LoVo cell proliferation in vitro. High expression of CDX2 therefore provides a promising strategy for the development of novel targeted treatments and gene therapy for CRC.

View Figures

View References

1	László L: Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. Magy Onkol. 54:383–394. 2010. View Article : Google Scholar : PubMed/NCBI
2	Akkad J, Bochum S and Martens UM: Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. Langenbecks Arch Surg. 400:129–143. 2015. View Article : Google Scholar : PubMed/NCBI
3	O’Connor JP, Rose CJ, Jackson A, et al: DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer. 105:139–145. 2011. View Article : Google Scholar
4	Akhavan-Niaki H and Samadani AA: Molecular insight in gastric cancer induction: an overview of cancer stemness genes. Cell Biochem Biophys. 68:463–473. 2014. View Article : Google Scholar
5	Natoli M, Christensen J, El-Gebali S, Felsani A and Anderle P: The role of CDX2 in Caco-2 cell differentiation. Eur J Pharm Biopharm. 85:20–25. 2013. View Article : Google Scholar : PubMed/NCBI
6	Lin ME, Huang D, Deng BH, Lv YS, Rong L and Yao YS: Expression and functional role of Cdx2 in intestinal metaplasia of cystitis glandularis. J Urol. 190:1083–1089. 2013. View Article : Google Scholar : PubMed/NCBI
7	Zheng J, Sun X, Wang W and Lu S: Hypoxia-inducible factor-1alpha modulates the down-regulation of the homeodomain protein CDX2 in colorectal cancer. Oncol Rep. 24:97–104. 2010.PubMed/NCBI
8	Aoki K, Tamai Y, Horiike S, Oshima M and Taketo MM: Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/− compound mutant mice. Nat Genet. 35:323–330. 2003. View Article : Google Scholar : PubMed/NCBI
9	Chawengsaksophak K, James R, Hammond VE, Köntgen F and Beck F: Homeosis and intestinal tumours in Cdx2 mutant mice. Nature. 386:84–87. 1997. View Article : Google Scholar : PubMed/NCBI
10	Olsen AK, Coskun M, Bzorek M, Kristensen MH, Danielsen ET, Jørgensen S, Olsen J, Engel U, Holck S and Troelsen JT: Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells. Carcinogenesis. 34:1361–1369. 2013. View Article : Google Scholar : PubMed/NCBI
11	Gross I, Duluc I, Benameur T, Calon A, Martin E, Brabletz T, Kedinger M, Domon-Dell C and Freund JN: The intestine-specific homeobox gene Cdx2 decreases mobility and antagonizes dissemination of colon cancer cells. Oncogene. 27:107–115. 2008. View Article : Google Scholar
12	Hong KD, Lee D, Lee Y, Lee SI and Moon HY: Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer. Am Surg. 79:353–360. 2013.PubMed/NCBI
13	Zheng JB, Sun XJ, Qi J, Li SS, Wang W, Ren HL, Tian Y, Lu SY and Du JK: Effects of homeodomain protein CDX2 expression on the proliferation and migration of lovo colon cancer cells. Pathol Oncol Res. 17:743–751. 2011. View Article : Google Scholar : PubMed/NCBI
14	Xie Y, Li L, Wang X, Qin Y, Qian Q, Yuan X and Xiao Q: Overexpression of Cdx2 inhibits progression of gastric cancer in vitro. Int J Oncol. 36:509–516. 2010.PubMed/NCBI
15	Wang W, Jin B, Li W, Xu CX, Cui FA, Liu B, Yan YF, Liu XX and Wang XL: Targeted antitumor effect induced by hTERT promoter mediated ODC antisense adenovirus. Mol Biol Rep. 37:3239–3247. 2010. View Article : Google Scholar
16	Bougel S, Renaud S, Braunschweig R, Loukinov D, Morse HC III, Bosman FT, Lobanenkov V and Benhattar J: PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells. J Pathol. 220:87–96. 2010. View Article : Google Scholar
17	Zhang P, Tan J, Yang DB, et al: Gene therapy using the human telomerase catalytic subunit gene promoter enables targeting of the therapeutic effects of vesicular stomatitis virus matrix protein against human lung adenocarcinoma. Exp Ther Med. 4:859–864. 2012.PubMed/NCBI
18	Hioki M, Kagawa S and Fujiwara T, Sakai R, Kojima T, Watanabe Y, Hashimoto Y, Uno F, Tanaka N and Fujiwara T: Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy. Int J Cancer. 122:2628–2633. 2008. View Article : Google Scholar : PubMed/NCBI
19	Gout S and Huot J: Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron. 1:69–83. 2008. View Article : Google Scholar
20	Jubb AM, Buffa FM and Harris AL: Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med. 14:18–29. 2010. View Article : Google Scholar
21	Law AY, Ching LY, Lai KP and Wong CK: Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. Mol Cell Endocrinol. 314:118–127. 2010. View Article : Google Scholar
22	Zhang J, Shi Q, Chen X, et al: Hypoxia-regulated neurotrophin-3 expression by multicopy hypoxia response elements reduces apoptosis in PC12 cells. Int J Mol Med. 30:1173–1179. 2012.PubMed/NCBI
23	Hu J, Stiehl DP, Setzer C, Wichmann D, Shinde DA, Rehrauer H, Hradecky P, Gassmann M and Gorr TA: Interaction of HIF and USF signaling pathways in human genes flanked by hypoxia-response elements and E-box palindromes. Mol Cancer Res. 9:1520–1536. 2011. View Article : Google Scholar : PubMed/NCBI
24	Tian Y, Sun XJ and Wang W and Wang W: TSST-1 regulated synergistically by 5HRE and CEAp activates lymphocytes to kill CEA-positive tumor cells specifically. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 26:525–529. 2010.In Chinese. PubMed/NCBI
25	Sun XJ, Lu L, Lu SY, Zhou PH and Wang W: The construction of 5HRE inducible TSST-1 gene therapy vector targeting for CEA-positive tumors. Chin J Cell Mol Immunol. 25:863–865. 2009.
26	Ren HL, Sun XJ, Zheng JB, Wang Z, Wang W and Cheng L: Over-expression CDX2 inhibits growth of colorectal transplanted tumors in mude mice. Chin J Cancer Biotherapy. 18:434–436. 2011.
27	Wang W, Sun X, Lu L, Zheng JB, Tian Y and Wang W: Cytotoxicity of lymphocytes activated by superantigen toxic-shock-syndrome toxin-1 against colorectal cancer LoVo cells. Mol Cell Biochem. 376:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
28	Li X, Wang K, Ren Y, et al: MAPK signaling mediates sinomenine hydrochloride-induced human breast cancer cell death via both reactive oxygen species-dependent and -independent pathways: an in vitro and in vivo study. Cell Death Dis. 5:e13562014. View Article : Google Scholar : PubMed/NCBI
29	Ji J and Zheng PS: Expression of Sox2 in human cervical carcinogenesis. Hum Pathol. 41:1438–1447. 2010. View Article : Google Scholar : PubMed/NCBI
30	Xu Y, Hou J, Liu Z, Yu H, Sun W, Xiong J, Liao Z, Zhou F, Xie C and Zhou Y: Gene therapy with tumor-specific promoter mediated suicide gene plus IL-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma. J Transl Med. 9:392011. View Article : Google Scholar : PubMed/NCBI
31	Zhang H, Liao ZK, Sun WJ, Huang C, Xiong J, Zhou FX, Xie CH and Zhou YF: Enhanced suicide gene therapy using a tumor-specific promoter in combination with cisplatin. Mol Med Rep. 2:1017–1022. 2009.PubMed/NCBI
32	Nemunaitis J, Tong AW, Nemunaitis M, et al: A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther. 18:429–434. 2010. View Article : Google Scholar :
33	Taketo MM: Roles of stromal microenvironment in colon cancer progression. J Biochem. 151:477–481. 2012. View Article : Google Scholar : PubMed/NCBI
34	Liu J, Harada H, Ogura M, Shibata T and Hiraoka M: Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts. Br J Cancer. 96:1871–1878. 2007. View Article : Google Scholar : PubMed/NCBI
35	Hryniuk A, Grainger S, Savory JG and Lohnes D: Cdx1 and Cdx2 function as tumor suppressors. J Biol Chem. 289:33343–33354. 2014. View Article : Google Scholar : PubMed/NCBI
36	Aoki K, Kakizaki F, Sakashita H, Manabe T, Aoki M and Taketo MM: Suppression of colonic polyposis by homeoprotein CDX2 through its nontranscriptional function that stabilizes p27Kip1. Cancer Res. 71:593–602. 2011. View Article : Google Scholar : PubMed/NCBI
37	Guo RJ, Funakoshi S, Lee HH, Kong J and Lynch JP: The intestine-specific transcription factor Cdx2 inhibits beta-catenin/TCF transcriptional activity by disrupting the beta-catenin-TCF protein complex. Carcinogenesis. 31:159–166. 2010. View Article : Google Scholar :
38	Krueger F, Madeja Z, Hemberger M, McMahon M, Cook SJ and Gaunt SJ: Down-regulation of Cdx2 in colorectal carcinoma cells by the Raf-MEK-ERK 1/2 pathway. Cell Signal. 21:1846–1856. 2009. View Article : Google Scholar : PubMed/NCBI
39	Olsen J, Espersen ML, Jess P, Kirkeby LT and Troelsen JT: The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review. Surg Oncol. 23:167–176. 2014. View Article : Google Scholar : PubMed/NCBI